Published: Sept. 7, 2023
Adenylosuccinic acid (ASA) is a small molecule dicarboxylate that could be strong clinical development candidate for inherited myopathies involving dysregulated purine nucleotide metabo-lism. Currently, there are no published pharmacokinetic/dynamic or toxicology data available, albeit 10-year trial in Duchenne muscular dystrophy patients suggests chronically safe drug. In this study, we tested the toxicity of ASA to cultured myoblasts vitro and acute systemic mice. non-toxic with an LD50> 5000mg/kg. Some background necrotic foci liver, kidney gastrointestinal tract were shown likely incidental but warrant follow-up sub-/chronic oral exposure studies.
Language: Английский